# EDGAR Filing Document

**Accession Number:** 0001676725
**File Stem:** 0000950170-25-103078
**Filing Date:** 2025-8
**Character Count:** 21808
**Document Hash:** 3ac6405729ee59110e70c00bd074dd37
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-103078.hdr.sgml**: 20250805

**ACCESSION NUMBER**: 0000950170-25-103078

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20250805

**DATE AS OF CHANGE**: 20250805

**EFFECTIVENESS DATE**: 20250805

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IDEAYA Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001676725
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 474268251
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-289256
- **FILM NUMBER:** 251185275

**BUSINESS ADDRESS:**
- **STREET 1:** 5000 SHORELINE CT, SUITE 300
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650-443-6209

**MAIL ADDRESS:**
- **STREET 1:** 5000 SHORELINE CT, SUITE 300
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ideaya Biosciences, Inc.
- **DATE OF NAME CHANGE:** 20160609

**As filed with the Securities and Exchange Commission on August 5, 2025** 

**Registration No. 333-**

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER*** 

***THE SECURITIES ACT OF 1933*** 

------

**IDEAYA Biosciences, Inc.** 

**(Exact name of Registrant as specified in its charter)** 

------

---

| | |
|:---|:---|
| **Delaware** | **47-4268251** |
| **(State or other jurisdiction of**<br>**incorporation or organization)**<br>| **(I.R.S. Employer**<br>**Identification Number)** |
| **5000 Shoreline Court, Suite 300** | **94080** |
| **South San Francisco, California**<br>**(Address of Principal Executive Offices)** | **(Zip Code)**<br>|

---

**IDEAYA Biosciences, Inc. 2023 Employment** 

**Inducement Award Plan** 

**(Full Title of the Plan)** 

------

**Yujiro Hata** 

**President and Chief Executive Officer** 

**IDEAYA Biosciences, Inc.** 

**5000 Shoreline Court, Suite 300** 

**South San Francisco, California 94080** 

**(650) 443-6209** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

------

***Copies to:*** 

**Mark V. Roeder, Esq.** 

**John C. Williams, Esq.** 

**Latham & Watkins LLP** 

**140 Scott Drive** 

**Menlo Park, California 94025** 

**(650) 328-4600** 

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**PART I** 

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS** 

The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Securities and Exchange Commission (the "Commission").

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

*In this Registration Statement, IDEAYA Biosciences, Inc. is sometimes referred to as "Registrant."*

**REGISTRATION OF ADDITIONAL SECURITIES** 

**PURSUANT TO GENERAL INSTRUCTION E OF FORM S-8**

This Registration Statement on Form S-8 (the "Registration Statement") is being filed with the Commission for the purpose of registering an additional 2,000,000 shares of common stock, par value $0.0001 per share ("common stock") of the Registrant issuable under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Award Plan, as amended (the "Inducement Plan") pursuant to which the Registrant had previously reserved 2,000,000 shares of common stock. Shares available for issuance under the Inducement Plan were previously registered on registration statements on Form S-8 filed with the Commission on March 7, 2023 ([<u>File No. 333-270334</u>](https://www.sec.gov/Archives/edgar/data/1676725/000119312523063052/d438859ds8.htm)) and August 6, 2024 ([<u>File No. 333-281301</u>](https://www.sec.gov/Archives/edgar/data/1676725/000119312524194956/d871726ds8.htm)) (collectively, the "Prior Registration Statements"). The Prior Registration Statements are currently effective. This Registration Statement relates to securities of the same class as those for which the Prior Registration Statements relate. The Inducement Plan was adopted and amended by the Registrant's board of directors without stockholder approval pursuant to Rule 5635(c)(4) of the Marketplace Rules of the Nasdaq Stock Market. Pursuant to Instruction E of Form S-8, the contents of the Prior Registration Statements are incorporated by reference herein to the extent not modified or superseded hereby or by any subsequently filed document, which is incorporated by reference herein, except for Item 8, which is being updated by this Registration Statement.

**Item 3. Incorporation of Documents by Reference.** 

The following documents previously filed by the Registrant with the Commission are incorporated by reference in this Registration Statement:

(a) the Registrant's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Commission on [<u>February 18, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001676725/000095017025022183/idya-20241231.htm) ;

(b) the Registrant's Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2025 and June 30, 2025, filed with the Commission on [<u>May 6, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001676725/000095017025064438/idya-20250331.htm) and [<u>August 5, 2025</u>](https://www.sec.gov/Archives/edgar/data/1676725/000095017025102967/idya-20250630.htm) , respectively;

(c) the Registrant's Current Reports on Form 8-K filed with the Commission on [<u>February 10, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001676725/000119312525023076/d934896d8k.htm) , [<u>April 2, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001676725/000119312525071309/d906746d8k.htm) , [<u>June 24, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001676725/000119312525145830/d909229d8k.htm) and [<u>June 27, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001676725/000119312525151257/d28084d8k.htm) ;

(d) the information specifically incorporated by reference into the Registrant's Annual Report on Form 10-K from the Registrant's Definitive Proxy Statement on Schedule 14A, filed with the Commission on [<u>April 30, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001676725/000095017025060530/idya-20250430.htm) ; and

(e) the description of the Registrant's common stock contained in the Registrant's "Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934" filed as [<u>Exhibit 4.3</u>](https://www.sec.gov/Archives/edgar/data/1676725/000095017025022183/idya-ex4_3.htm) to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2024 and any amendments or reports filed for the purpose of updating such description.

All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to the registration statement which indicates that all of the

------

shares of common stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents; except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under current Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, that is not deemed filed under such provisions. For the purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Under no circumstances will any information filed under current Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

**Item 8. Exhibits.** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Exhibit** |  | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Filed Herewith** |
| **Number** | **Exhibit Description** | **Form** | **Date** | **Number** |  |
| 4.1 | [<u>Amended and Restated Certificate of Incorporation.</u>](https://www.sec.gov/Archives/edgar/data/1676725/000119312519158427/d746735dex31.htm) | 8-K | 5-28-19 | 3.1 |  |
| 4.2 | [<u>Amended and Restated Bylaws.</u>](https://www.sec.gov/Archives/edgar/data/1676725/000119312519158427/d746735dex32.htm) | 8-K | 5-28-19 | 3.2 |  |
| 4.3 | [<u>Form of Common Stock Certificate.</u>](https://www.sec.gov/Archives/edgar/data/1676725/000119312519144721/d637842dex42.htm) | S-1/A | &nbsp;&nbsp;&nbsp;&nbsp;5-13-19 | 4.2 |  |
| 5.1 | [<u>Opinion of Latham & Watkins LLP.</u>](idya-ex5_1.htm) |  |  |  | X |
| 23.1 | [<u>Consent of Independent Registered Public Accounting Firm.</u>](idya-ex23_1.htm) |  |  |  | X |
| 23.2 | [<u>Consent of Latham & Watkins LLP (included in Exhibit 5.1).</u>](idya-ex5_1.htm) |  |  |  | X |
| 24.1 | [<u>Power of Attorney (included on signature page).</u>](#sig) |  |  |  | X |
| 99.1(a)# | [<u>2023 Employment Inducement Award Plan.</u>](https://www.sec.gov/Archives/edgar/data/1676725/000119312523063052/d438859dex993a.htm) | S-8 | 3-7-2023 | 99.3(a) |  |
| 99.1(b)# | [<u>Form of Stock Option Grant Notice and Stock Option Agreement under the 2023 Employment Inducement Award Plan.</u>](https://www.sec.gov/Archives/edgar/data/1676725/000119312523063052/d438859dex993b.htm) | S-8 | 3-7-2023 | 99.3(b) |  |
| 99.1(c)#  | [<u>Amendment, effective as of June 25, 2024, to the 2023 Employment Inducement Award Plan.</u>](https://www.sec.gov/Archives/edgar/data/1676725/000119312524194956/d871726dex991c.htm) | S-8 | 8-6-2024 | 99.1(c) |  |
| 99.1(d)# | [<u>Amendment, effective as of May 21, 2025, to the 2023 Employment Inducement Award Plan.</u>](https://www.sec.gov/Archives/edgar/data/1676725/000095017025102967/idya-ex10_3.htm) | 10-Q | 8-5-2025 | 10.3 |  |
| 107.1 | [<u>Filing Fee Table.</u>](idya_exfilingfees.htm) |  |  |  | X |

---

# Indicates management contract or compensatory plan.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in South San Francisco, California, on this 5th day of August, 2025.

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;**IDEAYA Biosciences, Inc.** | &nbsp;&nbsp;&nbsp;**IDEAYA Biosciences, Inc.** |
| &nbsp;&nbsp;&nbsp;By: | /s/ Yujiro Hata |
|  | &nbsp;&nbsp;&nbsp;Yujiro Hata |
|  | &nbsp;&nbsp;&nbsp;*President and Chief Executive Officer* |

---

**POWER OF ATTORNEY** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Yujiro Hata and Joshua Bleharski, Ph.D., and each of them acting individually, as his true and lawful attorneys-in-fact and agents, each with full power of substitution, for him in any and all capacities, to sign any and all amendments to this Registration Statement, including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule 462(b) increasing the number of securities for which registration is sought, and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Yujiro Hata<br>Yujiro Hata | President, Chief Executive Officer and Director<br>*(Principal Executive Officer)* | August 5, 2025 |
| /s/ Joshua Bleharski, Ph.D.<br>Joshua Bleharski, Ph.D. | Chief Financial Officer<br>*(Principal Financial Officer)* | August 5, 2025 |
| /s/ Terry Rosen, Ph.D.<br>Terry Rosen, Ph.D. | Chairman of the Board of Directors | August 5, 2025 |
| /s/ Garret Hampton, Ph.D.<br>Garret Hampton, Ph.D. | Director | August 5, 2025 |
| /s/ Catherine Mackey, Ph.D.<br>Catherine Mackey, Ph.D. | Director | August 5, 2025 |
| /s/ Scott Morrison<br>Scott Morrison | Director | August 5, 2025 |
| /s/ Jeffrey Stein, Ph.D. | Director | August 5, 2025 |
| Jeffrey Stein, Ph.D. |  |  |
| /s/ Wendy Yarno<br>Wendy Yarno | Director | &nbsp;&nbsp;&nbsp;&nbsp; August 5, 2025 |

---

------

## Exhibit 5.1

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**Exhibit 5.1**

140 Scott Drive

Menlo Park, California 94025

Tel: +1.650.328.4600 Fax: +1.650.463.2600

www.lw.com

FIRM / AFFILIATE OFFICES

![img113933597_0.jpg](img113933597_0.jpg)Austin Milan

Beijing Munich

Boston New York

Brussels Orange County

Century City Paris

August 5, 2025 Chicago Riyadh

Dubai San Diego

Düsseldorf San Francisco

Frankfurt Seoul

Hamburg Silicon Valley

Hong Kong Singapore

Houston Tel Aviv

London Tokyo

Los Angeles Washington, D.C.

Madrid

IDEAYA Biosciences, Inc.

5000 Shoreline Court, Suite 300

South San Francisco, CA 94080

Re: Registration Statement on Form S-8; 2,000,000 shares of Common Stock of IDEAYA Biosciences, Inc., par value $0.0001 per share

To the addressee set forth above:

We have acted as special counsel to IDEAYA Biosciences, Inc., a Delaware corporation (the "***Company***"), in connection with the registration by the Company of an aggregate of 2,000,000 shares of common stock of the Company, par value $0.0001 per share (the "***Shares***"), issuable under the Company's 2023 Employment Inducement Award Plan (as amended, the "***Plan***").

The Shares are included in a registration statement on Form S-8 under the Securities Act of 1933, as amended (the "***Act***"), filed with the Securities and Exchange Commission (the "***Commission***") on August 5, 2025 (the "***Registration Statement***"). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement

------

**August 5, 2025**<br>**Page 2**<br>

![img113933597_1.jpg](img113933597_1.jpg)

or the related prospectuses, other than as expressly stated herein with respect to the issuance of the Shares.

As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the "***DGCL***"), and we express no opinion with respect to any other laws.

Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers and have been issued by the Company against payment therefor in the circumstances contemplated by the Plan, assuming in each case that the individual issuances, grants or awards under the Plan are duly authorized by all necessary corporate action and duly issued, granted or awarded and exercised in accordance with the requirements of law and the applicable Plan (and the agreements and awards duly adopted thereunder and in accordance therewith), the issue and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL.

This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

Sincerely,

/s/ Latham & Watkins LLP

------

## Exhibit 23.1

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**Exhibit 23.1**

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of IDEAYA Biosciences, Inc. of our report dated February 18, 2025 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in IDEAYA Biosciences, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2024.

/s/ PricewaterhouseCoopers LLP<br>San Jose, California<br>August 5, 2025

------

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

**Exhibit 107.1**

**Calculation of Filing Fee Tables** 

**Form** S-8

(Form Type)

IDEAYA Biosciences, Inc.

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u> 

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  | **Security<br>Type** | **Security**<br>**Class**<br>**Title** | **Fee**<br>**Calculation**<br>**Rule** | **Amount**<br>**Registered** | **Proposed**<br> **Maximum** <br>**Offering**<br>**Price Per**<br>**Share** | **Maximum<br>Aggregate**<br>**Offering**<br>**Price** | **Fee**<br>**Rate** | **Amount of**<br>**Registration**<br>**Fee** |
| &nbsp;&nbsp;&nbsp;Fees to be Paid | 1 | Equity | 2023<br>Inducement<br>Plan<br>Common<br>Stock, par<br>value<br>$0.0001<br>per share<br>| 457(c)<br>and 457(h)<br>| 2000000 | $24.30 | <br>$48600000 | $0.00015310 | $7440.66 |
|  |  | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | $48600000 |  | $7440.66 |
|  |  | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** |  |  |  |
|  | 2 | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  |
|  |  | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  | $7440.66 |

---

(1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of Common Stock, par value $0.0001 per share ("Common Stock"), of IDEAYA Biosciences, Inc. (the "Registrant") that become issuable under the Registrant's 2023 Employment Inducement Award Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of Common Stock.

Estimated solely for purposes of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act, the proposed maximum offering price per share and proposed maximum aggregate offering price are based upon the average of the high and low prices of the Registrant's shares of Common Stock as reported on the Nasdaq Global Select Market on August 1, 2025, which date is within five business days prior to the filing of this Registration Statement.<br>

(2) The Registrant does not have any fee offsets.

------